LATANOPROST - Generic Drug Details

What are the generic drug sources for latanoprost and what is the scope of patent protection?

Latanoprost is the generic ingredient in seven branded drugs marketed by Sun Pharm, Thea Pharma, Amring Pharms, Apotex Inc, Bausch And Lomb, Carnegie, Epic Pharma Llc, Eugia Pharma, Fdc Ltd, Gland, Mankind Pharma, Micro Labs, Sandoz, Somerset, Upjohn, and Alcon Labs Inc, and is included in eighteen NDAs. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Latanoprost has fifty-three patent family members in thirty-one countries.

There are twenty drug master file entries for latanoprost. Eighteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for LATANOPROST

International Patents:	53
US Patents:	21
Tradenames:	7
Applicants:	16
NDAs:	18
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	18
Raw Ingredient (Bulk) Api Vendors:	77
Clinical Trials:	206
Drug Prices:	Drug price trends for LATANOPROST
Drug Sales Revenues:	Drug sales revenues for LATANOPROST
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LATANOPROST
What excipients (inactive ingredients) are in LATANOPROST?	LATANOPROST excipients list
DailyMed Link:	LATANOPROST at DailyMed

See drug prices for LATANOPROST

See drug sales revenues for LATANOPROST

Recent Clinical Trials for LATANOPROST

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alcon Research	PHASE4
Mayo Clinic	PHASE4
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,	PHASE4

See all LATANOPROST clinical trials

Generic filers with tentative approvals for LATANOPROST

Applicant	Application No.	Strength	Dosage Form
		0.005%	SOLUTION; OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Anatomical Therapeutic Chemical (ATC) Classes for LATANOPROST

S01EE	Prostaglandin analogues
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for LATANOPROST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	11,185,538		Y
Thea Pharma	IYUZEH	latanoprost	SOLUTION/DROPS;OPHTHALMIC	216472-001	Dec 13, 2022		RX	Yes	Yes	8,637,054		Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	11,197,853		Y
Carnegie	LATANOPROST	latanoprost	SOLUTION/DROPS;OPHTHALMIC	202077-001	Feb 11, 2013		DISCN	No	No
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	11,028,081
Sun Pharm	XELPROS	latanoprost	EMULSION;OPHTHALMIC	206185-001	Sep 12, 2018		DISCN	Yes	No	9,629,852		Y

Expired US Patents for LATANOPROST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	5,422,368
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	4,599,353
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	6,429,226
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	5,296,504
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	7,163,959

International Patents for LATANOPROST

Country	Patent Number	Title	Estimated Expiration
Morocco	34324
Brazil	112012033435
Singapore	186361
Mexico	2012014503
Japan	5646331
Chile	2012003684

Supplementary Protection Certificates for LATANOPROST

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0364417	9690031-1	Sweden		PRODUCT NAME: LATANOPROST
3461484	301101	Netherlands		PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108
0364417	97C0128	France		PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
3461484	2021C/515	Belgium		PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
3461484	122021000036	Germany		PRODUCT NAME: LATANOPROST, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND NETARSUDIL MESYLAT; REGISTRATION NO/DATE: EU/1/20/1502 20210107
3461484	SPC/GB21/033	United Kingdom		PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107

Latanoprost: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is the product scope for market analysis?

Latanoprost is a prostaglandin analog used primarily in ophthalmology for lowering intraocular pressure (IOP). The market is driven by chronic glaucoma and ocular hypertension treatment patterns and by ongoing patent and exclusivity timelines across multiple label formats.

How does demand behave in the ophthalmic market?

Ophthalmic glaucoma care is sticky because treatment is long-term and adherence depends on side-effect tolerability and dosing convenience. Demand dynamics for latanoprost typically follow four forces:

1. Chronic indication base

   • Patients remain on IOP-lowering therapy for extended periods.
   • Switching between prostaglandin analogs is common when efficacy and tolerability profiles differ.

2. Generic substitution pressure

   • As latanoprost patents and exclusivities expire by market, branded pricing compresses and volume shifts to generics.
   • Trade patterns show rapid penetration once first authorized generics or multiple suppliers enter.

3. Competitive class switching

   • The prostaglandin analog class includes multiple marketed agents that compete on dosing and ocular surface tolerability.
   • Fixed-dose combinations and newer prostaglandin-related products can shift share even if latanoprost remains a clinical workhorse.

4. Regulatory and procurement pathways

   • Hospital and national procurement tenders can lock in low-cost suppliers.
   • Formularies in major markets often favor cost-effective prostaglandin analogs.

Which competitive options shape latanoprost pricing power?

The financial trajectory of latanoprost is dominated by competitive intensity in glaucoma drops, including:

• Other prostaglandin analogs (class competition on efficacy and tolerability)
• Next-generation prostaglandin candidates and derivatives (share shift where they deliver meaningful patient outcomes)
• Combination products (IOP lowering synergy drives formulary adoption)
• Generics and biosavings (pricing resets once multi-source supply exists)

The result is that latanoprost’s market growth generally tracks category volume growth rather than branded product expansion, while net revenue declines after patent-to-generic transitions.

What does the financial trajectory look like post-patent and post-generic entry?

The typical financial shape for mature, single-ingredient ophthalmic drugs like latanoprost is:

• Branded peak phase: higher net pricing and steady volume.
• Exclusivity erosion: price compression after first generic launch.
• Multi-generic saturation: margins tighten, revenue becomes volume-led and increasingly dependent on contracting and tendering.
• Class competition drag: share shifts to newer or better-tolerated alternatives.

Revenue pattern expectation by lifecycle stage (directional)

Lifecycle stage	Price environment	Volume environment	Net revenue trajectory
Brand-led	Higher net price	Stable	Growth or plateau
First generic entry	Rapid price reset	Competing supply expands	Declining revenue
Multi-generic saturation	Further margin compression	High fill rates	Low-growth to decline
Class substitution / combos	Additional share loss risk	Category growth offsets some declines	Continued net decline or flatline

How do key market access mechanics impact financial outcomes?

For latanoprost, market access typically influences realized revenue as much as wholesale demand:

1. Tender-driven contracting

   • Public procurement can rapidly move usage to lowest-priced suppliers.
   • This reduces branded and single-supplier pricing latitude.

2. Pharmacy switching

   • For generics, pharmacy substitution can shift dispensing volumes quickly after launch.
   • Switching depends on local rules, reimbursement, and patient/caregiver preference.

3. Formulary behavior

   • Formularies in glaucoma frequently keep several prostaglandin options while promoting the most cost-effective.
   • If an alternative prostaglandin or combination enters with favorable profile, latanoprost share can erode even when total class volume rises.

Which quantitative market benchmarks apply?

Two widely used industry measures provide directionally consistent framing:

• Global pharmaceutical sales by molecule: tracks category and brand-versus-generic phases (often reported through specialty estimates).
• Unit growth vs value decline: indicates whether demand persists while pricing compresses.

For class-mature products like latanoprost, market value typically declines faster than units during generic saturation, driven by multi-source competition and tender pricing.

What does the patent and exclusivity structure imply for cash flows?

Cash flows for latanoprost in major markets generally reflect:

• Early exclusivity dominance: higher-margin branded period.
• Post-expiry declines: generic entry resets net pricing.
• Ongoing erosion: multiple suppliers and pack formats extend competitive pressure.

A practical consequence for financial modeling is that a “brand-like” CAGR is rarely sustainable once generic entry accelerates, and long-term revenue often resembles a declining-to-flat curve tied to category persistence.

How should investors and R&D planners interpret the trajectory?

Business implications

• Commercial returns become margin engineering: cost structure, sourcing, and tender competitiveness matter more than promotional spend.
• Portfolio strategy shifts: companies often defend the molecule with differentiated packaging, supply reliability, and contract participation rather than expecting premium pricing.
• Pipeline opportunities: new products in glaucoma tend to compete on differentiated delivery, tolerability, or combination efficacy, which changes the share allocation away from older prostaglandin analogs.

Financial modeling implications

• Use a post-generic price erosion curve rather than a steady-growth assumption.
• Split projections into:
  • Category unit volume (clinical demand persistence)
  • Share (class substitution and tendering)
  • Net price (generic mix and procurement pressure)

Key market dynamics by geography (high level)

Geography	Dominant dynamic	Expected effect on latanoprost value
US	Generic saturation and pharmacy switching	Continued pricing pressure; value declines or flatline
EU5	Tender and reimbursement-driven competition	Margin compression post-entry
UK	Procurement and reimbursement control	Low net pricing; volume-led performance
Major ex-US markets	Generic availability varies by time and supplier density	Faster value erosion where multi-source launches occur

What is the bottom-line financial trajectory expectation?

Across mature ophthalmic molecules, latanoprost’s financial trajectory is usually characterized by:

• Near-term stability after brand strength
• Pronounced value erosion following generic entry
• Long-term dependence on unit persistence and procurement execution
• Ongoing share pressure from competitive prostaglandin analogs and combination therapies

This pattern aligns with typical market behavior for established ophthalmology drops once patent barriers fall.

Key Takeaways

• Latanoprost’s market growth is largely category-driven, while net revenue is strongly controlled by generic substitution and procurement pricing.
• The financial trajectory typically shifts from branded margin to volume-led, margin-compressed performance after generic entry.
• Competitive class switching and combination product adoption can further pressure share even when total glaucoma drop demand rises.
• For modeling, separate units (demand persistence) from net price (generic mix and tendering) and share (class substitution).

FAQs

1) Why does latanoprost value decline faster than units in many markets?

Generic entry compresses net pricing while units keep growing due to ongoing chronic use.

2) What drives short-cycle revenue volatility for latanoprost?

Tender outcomes, pharmacy contract changes, and generic mix shifts can change realized price quickly.

3) Do improvements in tolerability materially change the latanoprost trajectory?

Only to the extent that they drive formulary retention versus switching within the prostaglandin analog class.

4) Is latanoprost growth more sensitive to market size or competitive behavior?

Competitive behavior is usually the dominant driver because glaucoma category growth is steady while share and pricing move sharply around exclusivity transitions.

5) How should companies allocate resources around a mature latanoprost franchise?

Focus shifts to supply reliability, contract execution, and cost position, because pricing power is limited in multi-source markets.

---

References (APA)

[1] FDA. (n.d.). Latanoprost prescribing information / product labels (accessed via Drugs@FDA). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] World Health Organization. (n.d.). ATC classification for latanoprost (S01EE01). WHO Collaborating Centre for Drug Statistics Methodology. https://www.whocc.no/atc_ddd_index/
[3] IQVIA Institute for Human Data Science. (various years). Global trends reports and forecasts on pharmaceutical markets and generics. IQVIA. https://www.iqvia.com/insights/the-iqvia-institute